157 related articles for article (PubMed ID: 2790792)
1. Effect of duration of exposure to verapamil on vincristine activity against multidrug-resistant human leukemic cell lines.
Cass CE; Janowska-Wieczorek A; Lynch MA; Sheinin H; Hindenburg AA; Beck WT
Cancer Res; 1989 Nov; 49(21):5798-804. PubMed ID: 2790792
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological, molecular, and cytogenetic analysis of "atypical" multidrug-resistant human leukemic cells.
Beck WT; Cirtain MC; Danks MK; Felsted RL; Safa AR; Wolverton JS; Suttle DP; Trent JM
Cancer Res; 1987 Oct; 47(20):5455-60. PubMed ID: 2888532
[TBL] [Abstract][Full Text] [Related]
3. Reversal of Vinca alkaloid resistance but not multiple drug resistance in human leukemic cells by verapamil.
Beck WT; Cirtain MC; Look AT; Ashmun RA
Cancer Res; 1986 Feb; 46(2):778-84. PubMed ID: 3455678
[TBL] [Abstract][Full Text] [Related]
4. Evidence for transcriptional control of human mdr1 gene expression by verapamil in multidrug-resistant leukemic cells.
Muller C; Goubin F; Ferrandis E; Cornil-Scharwtz I; Bailly JD; Bordier C; Bénard J; Sikic BI; Laurent G
Mol Pharmacol; 1995 Jan; 47(1):51-6. PubMed ID: 7838133
[TBL] [Abstract][Full Text] [Related]
5. Resistance to tetracycline, a hydrophilic antibiotic, is mediated by P-glycoprotein in human multidrug-resistant cells.
Kavallaris M; Madafiglio J; Norris MD; Haber M
Biochem Biophys Res Commun; 1993 Jan; 190(1):79-85. PubMed ID: 8093660
[TBL] [Abstract][Full Text] [Related]
6. Cytogenetic and molecular characterization of tumors in nude mice derived from a multidrug-resistant human leukemia cell line.
Hill AB; Beck WT; Trent JM
Cancer Res; 1988 Jan; 48(2):393-8. PubMed ID: 2891436
[TBL] [Abstract][Full Text] [Related]
7. Secretion of lysosomal enzymes by drug-sensitive and multiple drug-resistant cells.
Warren L; Jardillier JC; Ordentlich P
Cancer Res; 1991 Apr; 51(8):1996-2001. PubMed ID: 1672622
[TBL] [Abstract][Full Text] [Related]
8. Multidrug resistance in a human leukemic cell line selected for resistance to trimetrexate.
Arkin H; Ohnuma T; Kamen BA; Holland JF; Vallabhajosula S
Cancer Res; 1989 Dec; 49(23):6556-61. PubMed ID: 2573416
[TBL] [Abstract][Full Text] [Related]
9. Lack of reversal of daunorubicin resistance in HL60/AR cells by cyclosporin A.
Gollapudi S; Gupta S
Anticancer Res; 1992; 12(6B):2127-32. PubMed ID: 1363515
[TBL] [Abstract][Full Text] [Related]
10. A flow cell assay for evaluation of whole cell drug efflux kinetics: analysis of paclitaxel efflux in CCRF-CEM leukemia cells overexpressing P-glycoprotein.
Lin JT; Sharma R; Grady JJ; Awasthi S
Drug Metab Dispos; 2001 Feb; 29(2):103-10. PubMed ID: 11159798
[TBL] [Abstract][Full Text] [Related]
11. Cross-resistance of human multidrug-resistant cells to mitomycin C.
Yusa K; Sato W; Yamazaki A; Tsukahara S; Tsuruo T
Anticancer Res; 1991; 11(3):1301-4. PubMed ID: 1909515
[TBL] [Abstract][Full Text] [Related]
12. Role of differential drug uptake, efflux, and binding of etoposide in sensitive and resistant human tumor cell lines: implications for the mechanisms of drug resistance.
Politi PM; Sinha BK
Mol Pharmacol; 1989 Mar; 35(3):271-8. PubMed ID: 2564628
[TBL] [Abstract][Full Text] [Related]
13. Energy-dependent reduced drug binding as a mechanism of Vinca alkaloid resistance in human leukemic lymphoblasts.
Beck WT; Cirtain MC; Lefko JL
Mol Pharmacol; 1983 Nov; 24(3):485-92. PubMed ID: 6579344
[TBL] [Abstract][Full Text] [Related]
14. Characterization of monoclonal antibodies recognizing a Mr 180,000 P-glycoprotein: differential expression of the Mr 180,000 and Mr 170,000 P-glycoproteins in multidrug-resistant human tumor cells.
Meyers MB; Rittmann-Grauer L; O'Brien JP; Safa AR
Cancer Res; 1989 Jun; 49(12):3209-14. PubMed ID: 2566379
[TBL] [Abstract][Full Text] [Related]
15. Atypical multidrug resistance in a therapy-induced drug-resistant human leukemia cell line (LALW-2): resistance to Vinca alkaloids independent of P-glycoprotein.
Haber M; Norris MD; Kavallaris M; Bell DR; Davey RA; White L; Stewart BW
Cancer Res; 1989 Oct; 49(19):5281-7. PubMed ID: 2569932
[TBL] [Abstract][Full Text] [Related]
16. Structure-activity studies of amsacrine analogs in drug resistant human leukemia cell lines expressing either altered DNA topoisomerase II or P-glycoprotein.
Granzen B; Graves DE; Baguley BC; Danks MK; Beck WT
Oncol Res; 1992; 4(11-12):489-96. PubMed ID: 1363724
[TBL] [Abstract][Full Text] [Related]
17. Combined treatment of P-gp-positive L1210/VCR cells by verapamil and all-trans retinoic acid induces down-regulation of P-glycoprotein expression and transport activity.
Sulová Z; Macejová D; Seres M; Sedlák J; Brtko J; Breier A
Toxicol In Vitro; 2008 Feb; 22(1):96-105. PubMed ID: 17920233
[TBL] [Abstract][Full Text] [Related]
18. Study of sodium orthovanadate as a reverser of multidrug resistance on lymphoblastic leukemic CEM/VLB100 cells.
Colin M; Madoulet C; Baccard N; Arsac F; Jardillier JC
Anticancer Res; 1994; 14(6A):2383-7. PubMed ID: 7825977
[TBL] [Abstract][Full Text] [Related]
19. Isolation and characterization of an anthracycline-resistant human leukemic cell line.
Bhalla K; Hindenburg A; Taub RN; Grant S
Cancer Res; 1985 Aug; 45(8):3657-62. PubMed ID: 3860286
[TBL] [Abstract][Full Text] [Related]
20. Differential cellular retention of vincristine and vinblastine by cultured human promyelocytic leukemia HL-60/Cl cells: the basis of differential toxicity.
Ferguson PJ; Cass CE
Cancer Res; 1985 Nov; 45(11 Pt 1):5480-8. PubMed ID: 3863705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
